🕒 Wednesday 3 December 2025 Wed, 3 Dec 2025

Dateline Resources reports robust gold intercepts from recent drilling at its Colosseum Gold-REE Project in California, exceeding current resource grades and supporting an updated mineral resource estimate and ongoing feasibility study.

Koba Resources has reported exceptionally high tin grades up to 21.3% from initial sampling at its Mt Garnet Tin-Tungsten Project, Queensland, confirming a large, underexplored soil anomaly and advancing plans for drilling in early 2026.

Jindalee Lithium has completed its 2025 drilling program at the McDermitt Lithium Project and is advancing plans to list its US subsidiary on a national exchange, extending exclusivity with its merger partner.

OncoSil Medical’s interim OSPREY registry data reveals promising survival improvements for patients with unresectable locally advanced pancreatic cancer treated with OncoSil™ plus chemotherapy. The findings suggest a meaningful step forward in a field with limited effective options.

Tartana Minerals has postponed its planned drilling at the Beefwood copper-gold prospect in Far North Queensland due to persistent wet conditions, resulting in the loss of government funding and a rescheduled timeline for 2026.

Mammoth Minerals has raised A$7.5 million through a placement to accelerate exploration at its high-grade Excelsior and Bella Gold Projects in Nevada, aiming to unlock significant gold potential.

Polymetals Resources has raised $34.4 million through a share placement to boost exploration and production at its Endeavor Silver Zinc Mine, attracting strong institutional demand.

LTR Pharma has secured ethics approval for its Phase II SPONTAN clinical trial, focusing on pharmacokinetics and dosing in men aged 65 and older. Recruitment begins early 2026 with initial results expected mid-year.

Chariot Resources has amended its acquisition agreement for a Nigerian lithium portfolio, securing financing and extending the closing deadline to May 2026. The move reinforces exclusivity protections and paves the way for a smoother transaction completion.

Nexsen Limited has appointed internationally acclaimed surgeon-scientist Professor Shekhar Kumta to its board, aiming to fast-track clinical validation and regulatory approval for its rapid diagnostic platforms ahead of a planned 2026 market entry.

White Cliff Minerals has identified multiple high-priority copper targets along the 10km Teshierpi Fault Zone at its Rae Copper Project in Nunavut, Canada, following a comprehensive 2025 airborne electromagnetic survey. The findings extend known mineralisation at Danvers and set the stage for follow-up drilling in early 2026.

Aureka has reported compelling high-grade gold assay results from its ongoing drilling at the Irvine Project in Victoria, revealing a newly identified Resolution Footwall Vein and extending known mineralisation beyond the current resource boundary.

Prairie Lithium has completed critical groundwork at its Canadian lithium brine project, setting the stage for construction and commercial operations in 2026 amid rising lithium prices.

Transurban Group has announced a 34.0 cents per stapled security interim distribution for the half-year ending December 2025, maintaining its FY26 distribution guidance at 69.0 cents. The Distribution Reinvestment Plan will operate without a discount, signaling steady confidence amid ongoing macroeconomic uncertainties.

Microba Life Sciences has secured a $3.06 million R&D tax incentive refund for FY25, reinforcing its cash reserves and supporting ongoing advancements in gastrointestinal diagnostics and clinical therapeutics.

Phoslock Environmental Technologies is set to resume production at its Changxing factory after a four-year halt, signaling renewed confidence in market demand and operational stability.

QuickFee Limited has completed a $28.5 million capital return following the sale of its US Pay Now and Connect businesses, while updating its dividend policy to target regular shareholder cash distributions starting in FY26.

Transurban Group has announced a 34-cent unfranked dividend per stapled security for the six months ending December 2025, alongside a Dividend Reinvestment Plan with no discount.

Invion Limited has expanded its global rights to the Photosoft™ technology, gaining exclusive perpetual licenses across a broad range of human and animal diseases, including cancers and infectious diseases. This milestone-based deal positions Invion to accelerate clinical development and commercialisation worldwide.

Odyssey Gold has reported strong reverse circulation drilling results at its Tuckanarra Project, reinforcing the existing resource model and advancing plans for a resource upgrade. The Highway Deposit continues to demonstrate promising grade continuity and open pit potential.

Control Bionics Limited is set to acquire the remaining stake in Neuro Elite Athletics, integrating the NeuroBounce athletic performance program with its EMG technology to accelerate growth in key markets.

Island Pharmaceuticals has secured over $1 million through option exercises by directors and major shareholders, bolstering its cash reserves to advance the clinical and regulatory development of its broad-spectrum antiviral, Galidesivir.

BetMakers Technology Group has secured a favorable three-year content distribution agreement with Penn Entertainment, alongside strong digital customer growth that signals robust momentum for FY26 and beyond.

Transurban Group has announced a 34.0 cents per stapled security interim distribution for the half-year ending December 2025, reaffirming its full-year FY26 guidance of 69.0 cents. The Distribution Reinvestment Plan will proceed without a discount, signaling steady confidence amid ongoing market conditions.